Hey, all, welcome back to the real-life pharmacology podcast.

I'm your host, pharmacist Eric Christensen, and as always, I thank you for listening.

Today I'm going to cover drugs 131 through 135.

And our first medication is anoxiparin.

Brand name of this medication is Lovenox.

This is what's called a low molecular weight heparin,

abbreviated LMWH. And this medication is an anticoagulant, and it's going to primarily target

factor 10A. So again, these are clotting factors, which as expected, if we're using an anticoagulant,

we're going to thin the blood, and we're going to prevent those clotting factors from working.

So again, low molecular weight heparin primarily targets factor 10A, much more so than thrombin or factor 2a.

So that's kind of on a gradient there, but it tends to block the action of factor 10A

a little bit more so than 2A.

Ultimately, the blockade of this leads to its anticoagulant effect,

thins the blood, and it's going to help treat stem eDVT.

We can use it for post-op anticoagulation to prevent clotting in patients that aren't ambulatory.

Maybe they have cancer, for example, basically disease states or situations where they're more at risk

for throwing a clot or creating a clot in the body there. This medication is injection only.

The higher the dose that we're using, the more and more likely, we're probably going to be using

that for treatment

of DVTPE, for example, compared to DVTPE prophy prophy, or prevention, which then we can usually

get by with a lower dose there.

Kind of warnings, precautions, obviously bleed risk.

...